Meghan Scanlon, president of Boston Scientific’s urology division, expressed excitement over the firm’s recently closed acquisition of medical device company Axonics, which focuses on developing and commercializing differentiated products to treat urinary and bowel dysfunction. “We have been tracking Axonics quite closely during their early days and in the rapid ramp of their commercial success,” Scanlon told Medtech Insight. “This acquisition gets us into a very large and important adjacency in urology.”
Read the full article: Boston Scientific’s Head of Urology Says Axonics Acquisition ‘Brings a More Comprehensive Gender Balance’ //
Source: https://insights.citeline.com/medtech-insight/business/boston-scientifics-head-of-urology-says-axonics-acquisition-brings-a-more-comprehensive-gender-balance-FHNOS7SK5NFYBELA4LZB757VTI